EANS-News: Epigenomics AG: Life Technologies to Supply Crucial Components for Second-Generation Colorectal Cancer Blood Test

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products/Company Information/molecular diagnostic

Berlin, Germany, and Seattle, WA, U.S.A., May 6, 2011 (euro adhoc) -
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular
diagnosis company, today announced the signing of a supply agreement
with Life Technologies Corporation, a global provider of innovative
life science solutions. As the Original Equipment Manufacturer (OEM)
Life Technologies will supply its Dynabeads® MyOneTM SILANE and
buffers for Epigenomics' Epi proColon® 2.0 - the company's
second-generation colorectal cancer blood test that is in development
for the European and U.S. in vitro diagnostic (IVD) market.

Compared to the first generation test system, Epi proColon® 2.0
requires fewer components and handling steps, and can reach results
within eight hours, making it easier to automate on a wide range of
IVD automation solutions. A key feature of the new product is the use
of Dynabeads® MyOneTM SILANE, which are monosized, magnetic beads
that bind to nucleic acids (NAs, e.g. DNA) in biological samples. By
applying a magnetic field, the Dynabeads®-NA complex can be separated
and the NAs concentrated for diagnostic analysis such as the
detection of methylated DNA of the SEPT9 gene, the biomarker that is
targeted by Epi proColon® 2.0. Dynabeads® and associated reagents are
manufactured in compliance with the quality management systems ISO
13485:2003 in Life Technologies' facilities in Oslo, Norway.

All modifications to the assay incorporated into Epi proColon® 2.0
result in significantly improved clinical performance. In a
feasibility study that included 97 colorectal cancer cases and 159
colonoscopy-confirmed controls, the detection of cancer cases was
improved to a sensitivity of 91% at 87% specificity. In this study,
the new assay identified 21 out of 27 Stage I cancer cases (78%) and
25 out of 25 Stage II cancer cases (100%). This is critically
important since patients with Stage I and II of colorectal cancer
have a combined five-year survival of about 90% and early clinical
interventions can significantly improve survival. Stage III and Stage
IV cancers were detected at sensitivities of 92% and 100%,
respectively.

Dr. Uwe Staub, Senior Vice President Product Development at
Epigenomics commented: "Securing access to Life Technologies'
magnetic beads and reagents for our second-generation Septin9 test
has been very important for the development of Epi proColon® 2.0. By
including these crucial components into our assay along with some
other modifications, we were able to significantly improve clinical
performance and shorten the overall time to result allowing for
testing of higher volumes of samples."

"Life Technologies prides itself in providing sophisticated
technology for next-generation molecular diagnostics solutions that
can have a major impact on human health and disease," said Ole
Dahlberg, Country Manager Life Technologies Norway. "The supply
agreement between our two companies underscores the commitment to
develop and launch new diagnostic applications."

Epigenomics is currently transferring the manufacturing of its Epi
proColon® 2.0 assay to its contract manufacturer NextPharma based in
San Diego, CA, U.S.A. Epigenomics plans to conduct analytical and
clinical validation studies in the second half of 2011. The company
expects to submit a pre-market approval application (PMA) for Epi
proColon® 2.0 to the FDA before year-end 2011. -Ends-

Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics www.epigenomics.com is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade